Updated Guidelines Recommend Adding Pembrolizumab to Neoadjuvant Chemotherapy in TNBCJune 17th 2022
The ASCO’s expert panel released updated recommendations of pembrolizumab in combination with neoadjuvant chemotherapy for patients with stage II or stage III early triple-negative breast cancer
Efficacy of Neoadjuvant/Adjuvant Pembrolizumab in TNBCJune 16th 2022
Lajos Pusztai, MD, DPhil, discusses multiple analyses of the phase 3 KEYNOTE-522 clinical trial of pembrolizumab plus chemotherapy administered in the neoadjuvant or adjuvant setting to patients with triple-negative breast cancer versus placebo plus chemotherapy.
Case 2: Addressing ILD Associated With HER2-Targeted Therapy in mBCJune 15th 2022
Comprehensive discussion on the presence and management of interstitial lung disease in patients being treated for HER2+ metastatic breast cancer.
Consistent Survival Outcomes With Ribociclib Dose Reductions in HR+/HER2- Advanced Breast CancerJune 9th 2022
Patients with hormone receptor–positive, HER2-negative advanced breast cancer who had dose modifications of ribociclib had comparable overall survival outcomes to those given the standard dose.
Lasofoxifene Plus Abemaciclib Shows Clinically Meaningful Efficacy in Previously Treated ER+/HER2–/ESR1+ Metastatic Breast CancerJune 9th 2022
Results of the phase 1 ELAINEI trial will inform the activity of single-agent lasofoxifene in estrogen receptor-positive, HER2-negative metastatic breast cancer with ESR1 mutations.
Part 2: Managing Toxicities of Sacituzumab Govitecan in Metastatic TNBCJune 8th 2022
During a live virtual event, Rita Nanda, MD, discussed with participants how to address toxicities of sacituzumab govitecan and how to treat a patient who progresses after receiving this agent.
LUMINA Study Revels Radiotherapy is Not Needed for Some Luminal A Breast CancersJune 7th 2022
According to Timothy J. Whelan, MD, FASCO, radiotherapy is an inconvenient treatment. It can last daily for up to 5 weeks and it is a costly therapy. Study results shows that is can safely be omitted in the treatment of some patients with luminal A breast cancers.
Risk Factors Linked to Discontinuation of Adjuvant Abemaciclib in HR+/HER– Breast CancerJune 6th 2022
Several key risk factors seen in the monarchE trial of adjuvant abemaciclib could help early monitoring of patients with hormone receptor–positive, HER2-negative, node-positive high-risk early breast cancer to prevent discontinuation.
Benefit of Alpelisib/Fulvestrant Combo in HR+/HER- Breast Cancer Confirmed With Biomarker AnalysisJune 5th 2022
Combination of alpelisib and fulvestrant shows clinical benefit in patients with hormone receptor–positive, HER2-negative advanced breast cancer regardless of gene mutation status, according to a retrospective biomarker analysis.
Ribociclib With Switch Endocrine Therapy Beneficial Even After CDK4/6 Progression for HR+/HER2– Breast CancerJune 5th 2022
Treatment with ribociclib and an alternate endocrine therapy after progression on a prior CDK4/6 inhibitor improved progression-free survival over placebo and endocrine therapy in patients with HR-positive, HER2-negative unresectable or metastatic breast cancer, according to results of the randomized phase 2 MAINTAIN trial.
Patritumab Deruxtecan Elicits Promising Response in HER3-Expressing mBCJune 4th 2022
According to Ian E. Krop, MD, PhD, patritumab deruxtecan is responsible for producing clinically meaningful and durable antitumor activity in patients with HER3-expressing metastatic breast cancer, warranting further research.
Significant Survival Benefit Not Shown With Palbociclib Plus Letrozole in ER+/HER2- Advanced Breast CancerJune 4th 2022
First-line treatment with palbociclib plus letrozole demonstrated survival improvement vs letrozole monotherapy in patients with ER-positive/HER2-negative advanced breast cancer.
DESTINY-Breast03 Update Reinforces Safety of Trastuzumab Deruxtecan in Metastatic Breast CancerJune 4th 2022
A safety follow-up analysis of the randomized phase 3 DESTINY-Breast03 study reinforced the risk-benefit profile of trastuzumab deruxtecan compared with trastuzumab emtansine in patients with HER2-positive unresectable or metastatic breast cancer
Sacituzumab Govitecan Reduces Risk of Disease Progression in HR+/HER2- Metastatic Breast CancerJune 4th 2022
A 34% reduction in the risk of disease progression was observed with sacituzumab govitecan vs standard chemotherapy as treatment of patients with hormone-receptor-positive and HER2-negative metastatic breast cancer.
Management of HR+, HER2- Early-Stage Breast Cancer After DiagnosisJune 1st 2022
Physicians cover the options for a patient with hormone receptor–positive, HER2-negative, early-stage breast cancer, which course of action they would take, and the data supporting that choice.
Roundtable Discussion: Graff and Participants Debate Treatment Choices in TNBCJune 1st 2022
During a Targeted Oncology case-based roundtable event, Stephanie L. Graff, MD, discussed the case of a patient with triple-negative breast cancer who progressed following adjuvant chemotherapy and frontline carboplatin treatment.
Case 1: Selecting Adjuvant Therapy for Early-Stage HER2+ BCJune 1st 2022
Shifting their focus to the adjuvant setting, expert panelists review the optimal selection of therapy following surgery in early-stage HER2+ breast cancer.
Roundtable Discussion: Ademuyiwa Covers the Benefits and Challenges of Using Sacituzumab in Certain Populations of TNBCMay 27th 2022
During a case-based roundtable event, Foluso Olabisi Ademuyiwa, MD, MPH, MSCI and a group of peers discussed the benefits and challenges with using sacituzumab govitevan to treat a 48-year-old patients with triple-negative breast cancer.
Case 1: Neoadjuvant Treatment Armamentarium for Early-Stage HER2+ BCMay 25th 2022
Comprehensive insight on the neoadjuvant treatment armamentarium for early-stage HER2+ breast cancer and the appropriate selection of specific agents.
Part 1: Choosing Therapy for a Patient With Recurrent Metastatic TNBCMay 13th 2022
During a live virtual event, Rita Nanda, MD, discussed the choice of therapy for a patient whose metastatic triple-negative breast cancer recurred after adjuvant chemotherapy with paclitaxel.